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Matrix to predict rapid radiographic progression
of early rheumatoid arthritis patients from the
community treated with methotrexate or
leflunomide: results from the ESPOIR cohort
Bruno Fautrel1*, Benjamin Granger1, Bernard Combe2, Alain Saraux3, Francis Guillemin4 and Xavier Le Loet5
Abstract
Introduction: Early rheumatoid arthritis (RA) patients may show rapid radiographic progression (RRP) despite rapid
initiation of synthetic disease-modifying anti-rheumatic drugs (DMARDs). The present study aimed to develop a
matrix to predict risk of RRP despite early DMARD initiation in real life settings.
Methods: The ESPOIR cohort included 813 patients from the community with early arthritis for < 6 months; 370
patients had early RA and had received methotrexate or leflunomide during the first year of follow-up. RRP was
defined as an increase in the van der Heijde-modified Sharp score (vSHS) ≥ 5 points at 1 year. Determinants of RRP
were examined first by bivariate analysis, then multivariate stepwise logistic regression analysis. A visual matrix
model was then developed to predict RRP in terms of patient baseline characteristics.
Results: We analyzed data for 370 patients. The mean Disease Activity Score in 28 joints was 5.4 ± 1.2, 18.1% of
patients had typical RA erosion on radiographs and 86.4% satisfied the 2010 criteria of the American College of
Rheumatology/European League Against Rheumatism. During the first year, mean change in vSHS was 1.6 ± 5.5,
and 41 patients (11.1%) showed RRP. A multivariate logistic regression model enabled the development of a matrix
predicting RRP in terms of baseline swollen joint count, C-reactive protein level, anti-citrullinated peptide
antibodies status, and erosions seen on radiography for patients with early RA who received DMARDs.
Conclusions: The ESPOIR matrix may be a useful clinical practice tool to identify patients with early RA at high risk
of RRP despite early DMARD initiation.
Introduction
The care of rheumatoid arthritis (RA) has profoundly
evolved during the last decade because of new drug thera-
pies and the early treatment paradigm. RA requires rapid
referral to a rheumatologist [1-3] and early initiation of
disease modifying anti-rheumatic drugs (DMARDs) to
prevent long-term disease consequences, such as diabetes
or hypertension [4,5]. At the same time, regular adaptation
of DMARDs depending on disease activity - that is, RA
tight control - has become an additional standard in RA
management to achieve at least low disease activity and, if
possible, disease remission [3,6-12]. Implementation of
these recommendations in practice has led to better clini-
cal outcomes [6,8,13].
The choice of the first DMARD has been the topic of
many trials and guidelines. Methotrexate (MTX) has
been recommended as the anchor drug because it allows
for step-up strategies, that is, the addition of other syn-
thetic or biological DMARDs if adequate response is not
achieved with MTX monotherapy [3,9,14]. Leflunomide
is the alternate choice because both drugs seem to have
equivalent symptomatic and structural efficacy [15]. A
number of trials have assessed the potential benefit
of biologic DMARDs as first-line treatment for early
RA [16-18]. These intensive options have been consid-
ered more efficacious than MTX in trials with a static
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therapeutic strategy during the first year [18]. However,
in trials adopting dynamic step-up strategies, the overall
benefit of biologics as a first-line agent remained ques-
tionable [6,11,12,19-21]. In addition, several economic
evaluations reported that incremental cost-effectiveness
ratios of biologics as first-line treatment for early RA
are usually high and largely overtake the generally
accepted thresholds [22,23]. These conclusions rein-
forced the position of MTX (or leflunomide) as the opti-
mal first-line agent for early RA.
Despite current recommendations, for some patients,
MTX may be suboptimal as first-line therapy. Several trials
have shown substantial structural progression even with
MTX started rapidly after disease onset. This situation has
led to the development of the concept of rapid radio-
graphic progression (RRP), defined as structural damage
progression of at least five points of the van der Heijde-
modified Sharp score (vSHS); the cut-off of five points cor-
responds to the destruction of one small joint and to the
usually reported smallest detectable difference (SDD)
[24-26]. The rationale for this threshold has been con-
firmed in two different studies. In the BeSt trial, patients
with RRP during the first year of follow-up showed
increased functional limitations and structural damage
progression over eight years of follow-up, despite a tight
control-based therapeutic strategy [27]. These results are
consistent with another study of the ESPOIR cohort in
which patients with RRP during the first year in the
cohort, with a definition slightly different from the pre-
vious one, showed increased structural damage progres-
sion during the second and third years in the cohort [28].
The poor prognostic value associated with RRP is
important and may be addressed by the development of
prediction matrices to quantify the risk of RRP at one
year in terms of baseline data. Such matrices are a tool
than can identify patients with early RA who will show
inadequate response to MTX or its equivalent [24,29-31].
These matrices have been developed in randomized clini-
cal trials of patients with aggressive disease, who are not
generally representative of patients with early RA. There-
fore, the use of these matrices is limited in clinical prac-
tice, as was recently shown in the BRASS cohort [32].
Thus, we conducted a study of data for the ESPOIR
cohort, which enrolled patients with early arthritis from
the community (with or without unfavorable prognostic
factors). We aimed to develop a prediction algorithm and
matrix to identify patients with early RA at risk of RRP
despite early synthetic DMARD initiation.
Materials and methods
Patients
Between December 2002 and March 2005, 813 patients
with possible RA who were referred by rheumatologists
and general practitioners to one of 14 regional centers
were included in the ESPOIR cohort [33]. Inclusion cri-
teria were age 18 to 70 years, more than two swollen joints
for > 6 weeks and < 6 months, suspected or confirmed
diagnosis of RA, and not taking any DMARDs or steroids
except for < 2 weeks before enrollment. During the first
year, patients were followed every six months. Clinical and
biological data collected were disease activity by the Dis-
ease Activity Score in 28 joints-4 variables (DAS28(ESR)-
4v) [34] and functional ability by the Health Assessment
Questionnaire (HAQ) [35]. Radiographs of the hand and
feet (antero-posterior views) were obtained at each time,
as was information on therapeutic regimen. Treatment
strategies were not protocol-based in the ESPOIR cohort,
and patients received usual care by their rheumatologist.
The protocol of the ESPOIR Cohort study was approved
by the ethics committee of Montpellier University Hospi-
tal, France. All patients gave their signed informed consent
to participate in the cohort.
The current study involved data for ESPOIR patients
with an RA diagnosis according to their rheumatologist
and initiation of a first synthetic DMARD such as MTX
or leflunomide with demonstrated structural efficacy for
at least three months during the first year of follow-up in
the cohort.
Structural damage assessment
X-ray data were collected in the radiography coordinating
center and were read pair-wise by a well-trained investiga-
tor blinded to clinical evaluation (intra-class correlation
coefficient 0.99, SDD 0.966) [4]. Structural damage was
assessed qualitatively by the presence of typical RA ero-
sions, based on their location and aspect, and quantified
according to the vSHS [36,37]. RRP was defined as change
in vSHS (∆vSHS) ≥ 5 at 1 year [24,27,30,38].
Data management and statistical analysis
Quantitative variables are expressed as mean ± SD and
median. Qualitative data were expressed as number (%).
The predictors of ∆vSHS were selected by a conventional
two-step procedure.
The Mann-Whitney U test (for numerical data) and
Fisher’s exact test (for categorical data) were used in a uni-
variate analysis to establish the statistical significance of
the relation between candidate predictors and RRP, with-
out any a priori assumptions about the distribution of the
variables. All variables with P ≤ 0.1 were selected for mul-
tivariate regression analysis. To construct the prediction
matrix, quantitative variables selected in univariate analysis
were categorized, the optimal threshold being selected on
the basis of the variable distribution.
The multivariate analysis was based on a logistic regres-
sion model with a conventional backward stepwise proce-
dure validated by a forward stepwise procedure whereby
variables were optimized by the Akaike information
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criteria, with P < 0.05. The overall discrimination power of
the model was evaluated by receiver operating characteris-
tic curve (ROC) analysis and the calculation of the area
under the ROC (AUC). The fit of the model was assessed
by the Hosmer-Lemeshow test.
Matrix elaboration
The RRP prediction matrix was developed by use of the
model equation estimating the probability for one patient
with early RA to display RRP at one year for each combi-
nation of identified predictors. The 95% confidence inter-
vals of individual probabilities were calculated with 1,000
bootstrap replications, after removal of the outliers.
All tests involved use of R 2.12.1 (R Foundation,
Vienna, Austria).
Results
Patient characteristics
From the ESPOIR cohort, 370 patients (45.5%) had started
MTX (n = 335, mean dose 17.5 mg/week) or leflunomide
(n = 35, mean dose 20 mg/week). These patients, referred
to as ‘synthetic DMARD (SD)-treated patients’, were com-
parable to the rest of the cohort in terms of age, sex,
swollen and tender joints, and functional limitation. How-
ever, they had shorter disease duration, higher biological
inflammation values and more frequently were positive for
rheumatoid factor (RF) or anti-citrullinated peptide anti-
bodies (ACPA), had joint damage and satisfied the 2010
criteria of the American College of Rheumatology/Eur-
opean League Against Rheumatology (EULAR; Table 1).
This indicates that the selected patients were more likely
to have RA than those who did not receive one of the two
drugs, illustrating a channeling bias.
Patients who initially received MTX started the drug on
average 27.4 ± 15.4 weeks after disease onset. Among
them, 302 were still receiving MTX at 1 year, 19 had
switched to another SD and 11 to a biologic agent, mainly
TNF blockers (Table 2). Among patients receiving lefluno-
mide, only two switched to a biologic agent at one year.
Structural damage
For the SD-treated patients, the mean structural progres-
sion within the first year in terms of vSHS was 1.6 ± 5.5
(median 0), mainly because of progression of joint erosion
(Table 3, Additional file 1-Figure S1). The progression
occurred in 126 (34.1%) patients (∆vSHS ≥ SDD) with
Table 1 Baseline characteristics of the ESPOIR patients who received methotrexate or its equivalent as a first-line
biologic agent for rheumatoid arthritis.
SD-treated patients
(number = 370)
All ESPOIR patients
(number = 813)
Age, years 49.4 ± 11.4 (51.5) 48.1 ± 12.5 (50.1)
Female sex 271 (73.2%) 624 (76.7%)
Disease duration, weeks 15.2 ± 15.4 (57.7) 31.6 ± 37.1 (21.3)
Swollen joint count in 28 joints 7.9 ± 5.4 (7) 7.2 ± 5.4 (6)
Tender joint count in 28 joints 8.7 ± 6.9 (7) 8.4 ± 7 (6)
ESR, mm/1st hour 32.7 ± 25 (26) 29.4 ± 24.6 (22)
CRP, mg/L 24.8 ± 37.7 (11) 20.3 ± 32.4 (9)
DAS28(ESR)-4v 5.4 ± 1.2 (5.2) 5.1 ± 1.3 (5.1)
IgM RF positivity 204 (55.1%) 376 (45.8%)
ACPA positivity 185 (50%) 315 (38.8%)
Typical erosion on radiographs 66 (17.8%) 100 (13.6%)
vSHS score 6.02 ± 9.7 [54] 3.71 ± 5.71 [54]
ACR/EULAR 2010 criteria 316 (85.4%) 582 (79.1%)
HAQ score 1.03 ± 0.7 (1) 0.979 ± 0.684
First-line agent:
- No DMARDs n.a. 207 (25.5%)
- DMARDs without structural effect n.a. 117 (14.4%)
- Methotrexate or leflunomide 370 (100%) 396 (48.7%)
- Other DMARDs with structural effect n.a. 56 (6.9%)
- Tumor necrosis factor blockers alone or in combination n.a. 37 (4.6%)
Data are mean ± SD (median) or number (%); n.a.; not available. Baseline CRP level (normally < 10 mg/l), IgM and IgA RF (ELISA, Menarini, France; positive > 9 UI/
ml) and anti-CCP2 antibodies (ACPA; ELISA, DiaSorin, France; positive > 50 U/ml) were detected in all patients with the same technique in a central lab (Paris-
Bichat). ACPA, anti-citrullinated protein antibody; ACR/EULAR, American College of Rheumatology/European League Against Rheumatism; CRP, C-reactive protein;
DAS28(ESR)-4v, Disease Activity Score in 28 joints-4 variables, using erythrocyte sedimentation rate; DMARD, disease-modifying anti-rheumatic drugs; ESR,
erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IgM, immunoglobulin M; RF, rheumatoid factor; SD, synthetic DMARD; vSHS, van der
Heijde-modified Sharp score.
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mean vSHS change of 5.4 ± 7.0 (median 2). Among them,
41 had RRP, which represented 11.1% of all SD-treated
patients and 32.2% of patients with disease progression.
RRP determinants
The variables associated with RRP on univariate analysis
were disease duration, swollen joint count (SJC) and CRP
level (only when considered a categorical variable), RF and
ACPA status, alone or combined, and at least one typical
erosion seen on hand or foot radiographs (Table 4). Of
note, there were no differences between the two treatment
populations (MTX or leflunomide) with regard to these
determinants. The final multivariate model included only
SJC and CRP level (with two different thresholds for each),
as well as combined RF or ACPA status and presence of
typical RA erosions, which were predictors of RRP
(Table 5). ROC analysis confirmed the good discriminating
power of the model with an area under the curve (AOC)
of 0.754 [see Additional file 1, Figure S2].
Matrix elaboration
From these data, we developed a risk matrix (Figure 1,
Additional file 1, Figure S3) that indicates the probability
of RRP for patient profiles in terms of baseline SJC, CRP
level, ACPA status, and erosions seen on radiography.
For example, for a patient without typical RA erosions on
radiographs, no ACPA positivity, who receives MTX, the
probability of RRP at one year is 2% with SJC < 14 and
CRP level < 4 mg/L but 14% with SJC ≥ 20 and CRP level
≥ 35 mg/L. However, for a patient with typical RA ero-
sions on radiographs, ACPA positivity, who receives
MTX, the probability of RRP is 18% with SJC < 14 and
CRP level < 4 mg/L but 64% with SJC ≥ 20 and CRP level
≥ 35 mg/L. In terms of the high RRP probability, treat-
ment for the latter patients with only MTX or equivalent
could be considered suboptimal. Such patients repre-
sented 0.5% (n = 2) of the ESPOIR population if the 50%-
threshold is used (red boxes) and up to 12.4% (n = 46) if
the 25%-threshold is used (red and orange boxes).
Discussion
The present study allowed for the construction of a
matrix to predict the risk of RRP for patients with early
RA despite MTX or leflunomide therapy. Since RA is
considered a medical emergency [39] requiring rapid
referral to a rheumatologist [1-3] and early initiation of
DMARDs to prevent disease progression, the ESPOIR
matrix might help rheumatologists in daily practice
Table 2 Evolution of DMARD treatment and disease during the first year for ESPOIR patients with early rheumatoid
arthritis (RA).
First DMARD Treatment at 1 year
Type N Delay between RA onset and DMARD start
(weeks)a
N DAS28(ESR)-4v at
baseline
DAS28(ESR)-4v at 1
year
Methotrexateb 335 26.7 ± 11.6 (24.3) Methotrexate 302 5.3 ± 1.3 (5.2) 3.2 ± 2.7 (3.0)
35 ± 15.3 (39.4) Other synthetic
DMARD(s)c
19 5.3 ± 1.4 (5.3) 4.1 ± 1.5 (4.1)
30.5 ± 0.7 (21.6) Biologic agentd 11 5.7 ± 0.4 (5.5) 3.9 ± 0.9 (4.2)
Leflunomide 35 48.9 ± 11.6 (46.9) Methotrexate 9 5.8 ± 1.3 (5.6) 4.0 ± 2.7 (2.9)
22.5 ± 15.3 (20.7) Other synthetic
DMARD(s)
24 5.4 ± 1.4 (5.5) 3.3 ± 1.5 (3.0)
37.8 ± 0.7 (37.8) Biologic agentd 2 5.9 ± 0.4 (5.9) 4.2 ± 0.9 (4.2)
Data are mean ± SD (median). aDelay between RA onset and DMARD start (weeks) (P = 0.479): Methotrexate: 27.2 ± 15.1 (24.7); Leflunomide: 30.1 ± 18.1 (24.6);
bat one year: one patient did not receive any DMARDs and data for two patients were not available; cleflunomide or salazopyrine; dadalinumab, etanercept,
infliximab or anakinra. DAS28(ESR)-4v, Disease Activity Score in 28 joints-4 variables, using erythrocyte sedimentation rate; DMARD, disease-modifying anti-
rheumatic drugs; N, number.
Table 3 Structural disease progression in patients with early RA who received DMARDs and the entire ESPOIR cohort.
SD-treated patients All ESPOIR patients
All patients (number = 370) (number = 736a)
- ∆vSHS total 1.6 ± 5.5 (0) 0.96 ± 4.4 (0)
- ∆vSHS erosion 1.5 ± 4.7 (0) 0.96 ± 3.8 (0)
- ∆vSHS narrowing 0.2 ± 1.8 (0) 0.01 ± 1.81 (0)
Patients with structural progressionb (number = 126, 34.1%) (number = 187, 25.4%)
- ∆vSHS total 5.4 ± 7.0 [54] 5.0 ± 6.3 [54]
- ∆vSHS ≥ 5 points (RRP) 41 (11.1%) 58 (7.9%)
Data are mean ± SD (median) or number (%).aX-ray data were available for only 736 patients; bStructural progression was defined as ∆vSHS ≥ 1 point (that is, the
smallest detectable difference). DMARD, disease-modifying anti-rheumatic drugs; RRP, rapid radiographic progression; SD, synthetic DMARD; ∆vSHS, change in
van der Heijde-modified Sharp score.
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identify patients at high risk of SD failure, and thus
make better-informed and evidence-based therapeutic
decisions. The community-based nature of the study is
one of the major strengths of this work, which makes
patient typology more representative of daily clinical
practice than that of randomized clinical trials. The
ESPOIR cohort included patients with early arthritis and
possible, probable or definite diagnosis of RA. However,
no specific disease activity level or prognostic markers
of severity were required for inclusion [33].
For several reasons, we focused on patients who had
started receiving MTX or leflunomide during the observa-
tion period. First, therapeutic decisions were not protocol-
based in the ESPOIR cohort, and patients received treat-
ment according to standard care by their rheumatologist.
Patients with the most active or structurally aggressive dis-
ease were more likely to receive the most effective drugs
such as MTX or TNF blockers, which highlights a chan-
neling bias [4,40]. Four gross therapeutic strategies can be
distinguished: no DMARD during the first year in the
cohort, DMARDs without demonstrated structural efficacy
such as hydroxychloroquine, DMARDs with demonstrated
structural benefit such as MTX or leflunomide, or biolo-
gics such as TNF blockers. Without any adjustment, the
Table 4 Association of main baseline characteristics of patients with early RA and rapid radiographic progression
(RRP) of rheumatoid arthritis (univariate analysis).
With RRP
(number = 41)
Without RRP
(number = 329)
P valuea
Age, years 49.8 ± 12 (52.7) 49.3 ± 11.5 (7) 0.6
Sex 31 (75.6%) 240 (73%) 0.85
Disease duration, weeks 18.6 ± 8.4 (18.6) 14.7 ± 8.1 (13) 0.007
SJC in 28 joints 8.6 ± 6.1 (8) 7.8 ± 5.3 (7) 0.5
< 14 31 (75.6) 285 (86.6)
14 to 20 6 (14.6) 32 (9.7) 0.08
≥ 20 4 (12.2) 12 (3.6)
TJC in 28 joints 8.3 ± 6.3 (7) 8.7 ± 6.9 (7) 0.97
ESR, mm/1 hr 32.6 ± 21.3 (30) 32.7 ± 25.4 (25) 0.5
CRP, mg/L 26.2 ± 27.9 (14) 24.6 ± 38.7 (11) 0.12
< 4 4 (9.7) 89 (27.1)
4 to 35 25 (61) 168 (51.1) 0.04
≥ 35 12 (29.3.8) 72 (21.9)
Elevated ESR or CRP level 38 (90.3) 289 (87.8) 0.45
DAS28(ESR)-4v 5.3 ± 1.2 (5.4) 5.3 ± 1.2 (5.2) 0.8
RF positivity 29 (70.7) 175 (53.2) 0.04
ACPA positivity 31 (75.6) 154 (46.8) 0.0008
RF or ACPA positivity 32 (78) 190 (57.8) 0.01
HAQ score 0.95 ± 0.6 (1) 1.04 ± 0.7 (1) 0.5
Typical RA erosion 18 (44) 48 (14.6) < 0.0001
Prednisone ≥ 7.5 mg/d 2 (4.9) 35 (10.6) 0.4
≥ 5 mg/d 7 (17.7) 91 (27.7) 0.19
Delay before 1st DMARD initiation ≥ 6 months after RA onset 22 (53.7) 147 (44.7) 0.32
Satisfaction of 2010 ACR/EULAR criteria 38 (92.7) 278 (84.5) 0.24
Data are mean ± SD (median) or number (%). RRP-positive status was defined by progression of the vSHS total score ≥ 5 points between baseline and one year
(of note, among the 46 patients with RRP, 44 had progression with vSHS erosion score ≥ 5 points and 13 with vSHS narrowing score ≥ 5 points). aStudent t test
or Mann-Whitney U test for continuous variables and Fischer exact test for categorical variables, with P < 0.1. ACPA, anti-citrullinated protein antibody; ACR/
EULAR, American College of Rheumatology/European League Against Rheumatism; CRP, C-reactive protein; DAS28(ESR)-4v, Disease Activity Score in 28 joints-4
variables, using erythrocyte sedimentation rate; DMARD, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment
Questionnaire; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; vSHS, van der Heijde-modified Sharp score.
Table 5 Determinants of rapid radiographic progression
of RA for patients with early RA who received DMARDs
(multivariate analysis).
Estimate Standard
Error
z
value
P
value
Swollen joint count 14 to
20
0.27 0.53 0.52 0.60
Swollen joint count ≥ 20 1.25 0.68 1.84 0.06
CRP 4 to 35 mg/L 0.83 0.57 1.45 0.15
CRP ≥ 35 mg/L 0.86 0.63 1.36 0.17
ACPA status 1.11 0.40 2.75 0.006
Typical RA erosion 1.31 0.63 3.53 0.0004
Intercept -3.94 0.58 -6.74 1.62e-
11
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DMARD,
disease-modifying anti-rheumatic drugs; RA, rheumatoid arthritis
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progression in vSHS was substantially higher in the latter
two groups, which shows that patients receiving the most
efficacious drugs were identified by their rheumatologists
as being likely to have active and erosive RA [4]. The use
of propensity scores could in theory adjust on these con-
founding factors. Although different models were tested,
we did not achieve a satisfactory adjustment, able to make
the different treatment groups comparable at baseline.
Thus, the analysis was stratified and only focused on the
more clinically relevant and adequately sample-sized
group, that is, the group of patients treated with either
MTX or leflunomide, the two most widely used therapies
in early RA. Although several synthetic DMARDs have
shown their ability to prevent structural damage progres-
sion, only two seem to have similar efficacy (that is, MTX
and leflunomide) in a recent systematic literature review
conducted under the auspices of EULAR [15]. Therefore,
sulfasalazine, gold salts or other synthetic DMARDs were
excluded in the patient selection process. This choice also
appeared more clinically relevant because this therapeutic
option is considered optimal for most patients [17]. Our
data indicate that other options, for example, biologics,
could be better for the patients with high RRP risk (red
boxes in Figure 1). In an explanatory analysis, the patients
treated with TNF-blockers as first line agent (n = 37, with
complete data available for only 27) were plotted in the
matrix; their observed RRP risk was lower than the
expected RRP risk.
Several prediction matrices have been recently proposed.
Three were derived from results of randomized controlled
clinical trials assessing the efficacy of TNF-blocking agents
[20,24,29-31,41], so patients with early RA with substantial
disease activity and/or severity were included as candidates
for biologics. Moreover, in these trials, therapeutic adapta-
tion was protocol-based - fixed strategy over one year or
tight control according to a predefined scheme - which, in
both cases, is not quite consistent with usual care in which
treatment adaptations are often looser, thus enabling sub-
optimal disease control [42,43]. Only one algorithm was
developed from data from an early RA cohort, SONORA,
in Canada and the United States but has not been pub-
lished [44]. The predictors identified to build the different
matrices were partly overlapping. In the ASPIRE matrix
[24], the three constitutive variables comprising the matrix
were RF status, SJC and erythrocyte sedimentation rate
(ESR); baseline joint damage was not included, although it
is a strong predictor of further structural damage in RA
[45]. In the BeSt study [30], RF or ACPA status, number
of erosions at baseline and CRP level but not SJC, another
marker of disease severity, were used in the risk matrix
[45]. In the SWEFOT trial [20,29,31,41], the proposed
matrix included smoking status, CRP level and erosions at
baseline; ACPA status was not significantly associated
with RRP, which is not consistent with the literature [45].
This finding may be explained in part by the confounding
of the strong association of smoking status and ACPA sta-
tus [46-48]. The ESPOIR matrix may appear more com-
prehensive than the other matrices because it included all
the known RA prognostic markers. Of interest, in the
observational cohort SONORA, the proposed matrix
included most of the same parameters: baseline DAS28
(ESR)-4v, vSHS and ACPA status [44].
Our study has some limitations. The first pertains to
MTX dosage, because several doses have been proposed in
the literature. Our patients received 17.5 mg/week, on
average, which may be considered slightly lower than that
used in other settings [49]. Another concern relates to
low-dose prednisone therapy, which has been efficacious
in preventing structural damage progression [50-52]. In
the ESPOIR cohort, 42% of the patients received steroids
during the first year of follow-up, with a mean dose of 5.5
± 3.7 mg/d (median 5 mg/d). This daily dose was quite
  Absence of typical RA erosion on radiographs  Presence of typical RA erosions on radiographs     
  SJC < 14 14 ø SJC < 20 SJC œ 20 SJC < 14 14 ø SJC < 20 SJC œ 20    
ACPA 
positivity 
CRP œ 35 0.12 [0.05; 0.23] 
0.16  
[0;0.91] 
0.33 
[0.10; 0.84] 
0.34 
[0.17; 0.54] 
0.40  
[0.16; 0.67] 
0.64  
[0.28; 0.88]   RRP Risk 
4 ø CRP < 35 0.12 [0.07; 0.19] 
0.16  
[0;0.9] 
0.32 
[0.09; 0.63] 
0.33  
[0.19; 0.50] 
0.40  
[0.18; 0.52] 
0.64  
[0.24; 0.88]   ≥ 50% 
CRP < 4 0.06  [0.01; 0.13] 
0.07  
[0.01; 0.24] 
0.17 
[0.03; 0.52] 
0.18  
[0.04; 0.35] 
0.22  
[0.04; 0.52] 
0.43  
[0.07; 0.82]   25 ø   < 50% 
ACPA 
negativity 
CRP œ 35 0.04 [0.01; 0.10] 
0.06  
[0.01; 0.16] 
0.14  
[0.03; 0.33] 
0.15  
[0.04; 0.31] 
0.18  
[0.05; 0.43] 
0.37  
[0.08; 0.68]   10 ø   < 25% 
4 ø CRP < 35 0.04  [0.01; 0.08] 
0.06 
[0.01; 0.15] 
0.14  
[0.03; 0.33] 
0.14  
[0.04; 0.28] 
0.18  
[0.05; 0.44] 
0.37  
[0.08; 0.69]   < 10% 
CRP < 4 0.02  [0; 0.04] 
0.03  
[0; 0.08] 
0.07 
[0.01; 0.19] 
0.07 
[0.02; 0.15] 
0.08  
[0.01; 0.24] 
0.20 
[0.02; 0.52]    
 
Figure 1 ESPOIR prediction matrix. ESPOIR prediction matrix for use in daily practice in assessing the risk of rapid radiographic progression
(RRP; change in vSHS ≥ 5 points at 1 year) in patients with early rheumatoid arthritis in terms of baseline characteristics. ACPA, anti-citrullinated
protein antibody; CRP, C-reactive protein (mg/L); vSHS, van der Heijde-modified Sharp score.
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low, and our analyses did not reveal any association
between prednisone intake and RRP.
The quality of care could not be assessed in the
ESPOIR cohort, especially in terms of optimal or subopti-
mal timing of RA diagnosis or MTX introduction, two
key elements of future disease control [3,4,13,53]. More-
over, the implementation and respect of tight control was
not identifiable in the cohort and may have had an
impact on structural progression [42]. However, this
situation may suggest that our results are representative
of clinical practice, as stated above. Another important
limitation is the lack of validation of our matrix in a dif-
ferent population, which is a limitation in all RA
matrices. Attempts have been made to cross-validate the
ASPIRE, BeSt and SWEFOT matrices in the SWEFOT
trial population [41] and in the BRASS cohort, an estab-
lished RA cohort [32]. In both cases, the performance of
the different matrices in different populations was disap-
pointing. Whether the more comprehensive ESPOIR
matrix may be optimal in different populations remains
to be demonstrated, as well as the performance of the
other matrices in the ESPOIR population (work in pro-
gress). Finally, all matrices have limitations inherent in
their development that relate to multivariate analyses
performed in limited samples of patients. The RRP risk
was thus a predicted risk as opposed to an observed risk.
Some of the matrix boxes were rather poorly populated
and may explain the only fair performance of matrices in
populations different from those in which they have been
developed.
Conclusions
The ESPOIR matrix is a novel tool developed in a real life
setting to help rheumatologists in usual daily practice to
identify patients with early RA at high risk of RRP despite
MTX or leflunomide therapy. The performance of this
tool needs to be validated in other patient populations.
Then, it will become a quite relevant instrument to guide
rheumatologists in their therapeutic decision making,
especially to detect patients for whom MTX may not be
optimal therapy.
Additional material
Additional file 1: Supplemental figures. Figure S1: Cumulative plot of
the vSHS score variation between baseline and month 12. Figure S2: Fit
of the final model estimated by receiver operating characteristic curve
analysis. Figure S3: Observed patient frequencies in the different cells of
the ESPOIR matrix.
Abbreviations
ACPA: anti-citrullinated peptide antibodies; ACR: American College of
Rheumatology; AUC: area under the curve; CRP: C-reactive protein; DMARD:
disease-modifying anti-rheumatic drugs; DAS28(ESR)-4v: disease activity score
in 28 joints-4variables, using erythrocyte sedimentation rate; ESR: erythrocyte
sedimentation rate; EULAR: European League Against Rheumatism; HAQ:
Health Assessment Questionnaire; MTX: methotrexate; RA: rheumatoid
arthritis; RF: rheumatoid factor; ROC curve: receiver operating characteristic
curve; RRP: rapid radiographic progression; SD: synthetic DMARD; SDD:
smallest detectable difference; TNF: tumor necrosis factor; vSHS: van der
Heijde-modified Sharp score; SJC: swollen joint count; TJC: tender joint
count; TNF: tumor necrosis factor.
Acknowledgements
We thank the French rheumatologists who referred their patients to the
ESPOIR cohort in the following rheumatology departments: Amiens (P.
Fardellone, P. Boumier), Bordeaux (T. Schaeverbeke), Brest (A. Saraux), Lille (R.
M. Flipo), Montpellier (B. Combe), Paris-Bicêtre (X. Mariette), Paris-Bichat (O.
Meyer), Paris-Cochin (M. Dougados), Paris-La Pitié (B. Fautrel), Paris-St Antoine
(F. Berenbaum), Rouen (X. Le Loët, O. Vittecoq), Strasbourg (J. Sibilia),
Toulouse (A. Cantagrel), and Tours (P. Goupille).
We are grateful to N. Rincheval for data management and expert
monitoring; to S. Martin for performing all the centralized assays of CRP, IgA
and IgM rheumatoid factors, and anti-CCP antibodies; and to S. Harvard and
L. Smales for translation and copyediting. We also thank Drs Nathan
Vastesaeger, Gérard Trape and Cornelia R Allaart for thoughtful discussions
about the ASPIRE and BeSt matrices.
An unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for
the first five years of the ESPOIR cohort study. Two additional grants from
the INSERM were obtained to support part of the biological database. The
French Society for Rheumatology, Abbott, Amgen, and Wyeth also
supported the ESPOIR cohort study.
The present work has been institutionally supported by an unrestricted
grant from GERCER (Groupe d’Etudes et de Recherches Cliniques En
Rhumatologie), Paris, France.
Author details
1Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-08 EEMOIS; AP-HP
Pitié Salpêtrière Hospital, Department of Rheumatology, 75013 Paris, France.
2Montpellier I University; Department of Rheumatology, Lapeyronie Hospital,
UMR 5535, 34000 Montpellier, France. 3Brest University; Department of
Rheumatology, La Cavale Blanche University Hospital, 29000 Brest, France.
4Lorraine University, Paris-Descartes University, EA 4360 APEMAC – Inserm,
CIC-EC CIE6, CHU de Brabois, 54505 Vandoeuvre-lès-Nancy, France.
5Rheumatology Department, Rouen University Hospital & INSERM U905,
Institute for Research and Innovation in Biomedicine, Rouen University;
76031 Rouen, France.
Authors’ contributions
The design of the study was conceived by BF, BG, BC and XL. Data
collection, management and analysis were performed by BF, BC, AS, FG and
XL. All authors participated in the interpretation of the results and
manuscript writing. All have read and approved the final version of the
manuscript for publication.
Competing interests
The authors declare that they have no competing interests.
Received: 12 June 2012 Revised: 11 October 2012
Accepted: 6 November 2012 Published: 19 November 2012
References
1. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS: Early
referral recommendation for newly diagnosed rheumatoid arthritis:
evidence based development of a clinical guide. Ann Rheum Dis 2002,
61:290-297.
2. Fautrel B, Constantin A, Morel J, Vittecoq O, Cantagrel A, Combe B,
Dougados M, Le Loet X, Mariette X, Pham T, Puechal X, Sibilia J, Soubrier M,
Ravaud P: Recommendations of the French Society for Rheumatology.
TNFalpha antagonist therapy in rheumatoid arthritis. Joint Bone Spine
2006, 73:433-441.
3. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M,
Emery P, Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola E,
Nielsen H, Silman A, Smolen J, Yazici H: EULAR recommendations for the
management of early arthritis: report of a task force of the European
Fautrel et al. Arthritis Research & Therapy 2012, 14:R249
http://arthritis-research.com/content/14/6/R249
Page 7 of 9
Standing Committee for International Clinical Studies Including
Therapeutics (ESCISIT). Ann Rheum Dis 2007, 66:34-45.
4. Lukas C, Combe B, Ravaud P, Sibilia J, Landew R, van der Heijde D:
Favorable effect of very early disease-modifying antirheumatic drug
treatment on radiographic progression in early inflammatory arthritis:
Data from the Etude et Suivi des polyarthrites indifferenciees recentes
(study and followup of early undifferentiated polyarthritis). Arthritis
Rheum 2011, 63:1804-1811.
5. Pincus T, Gibofsky A, Weinblatt ME: Urgent care and tight control of
rheumatoid arthritis as in diabetes and hypertension: better treatments
but a shortage of rheumatologists. Arthritis Rheum 2002, 46:851-854.
6. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC,
Dijkmans BA: Aiming at low disease activity in rheumatoid arthritis with
initial combination therapy or initial monotherapy strategies: the BeSt
study. Clin Exp Rheumatol 2006, 24:S77-82.
7. Fransen J, Moens HB, Speyer I, van Riel PL: Effectiveness of systematic
monitoring of rheumatoid arthritis disease activity in daily practice: a
multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005,
64:1294-1298.
8. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W,
Porter D: Effect of a treatment strategy of tight control for rheumatoid
arthritis (the TICORA study): a single-blind randomised controlled trial.
Lancet 2004, 364:263-269.
9. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G,
Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-
Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-
Mola E, Montecucco C, Schoels M, van der Heijde D: Treating rheumatoid
arthritis to target: recommendations of an international task force. Ann
Rheum Dis 2010, 69:631-637.
10. Svensson B, Schaufelberger C, Teleman A, Theander J: Remission and
response to early treatment of RA assessed by the Disease Activity
Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy.
Rheumatology (Oxford) 2000, 39:1031-1036.
11. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van
Zeben D, Kerstens PJ, Gerards AH, van Groenendael JH, Hazes JM,
Breedveld FC, Allaart CF, Dijkmans BA: Limited efficacy of conventional
DMARDs after initial methotrexate failure in patients with recent onset
rheumatoid arthritis treated according to the disease activity score. Ann
Rheum Dis 2007, 66:1356-1362.
12. van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK,
van Zeben D, Kerstens PJ, Hazes JM, van Schaardenburg D, Breedveld FC,
Dijkmans BA, Allaart CF: Clinical and radiological efficacy of initial vs
delayed treatment with infliximab plus methotrexate in patients with
early rheumatoid arthritis. Ann Rheum Dis 2009, 68:1153-1158.
13. Escalas C, Dalichampt M, Combe B, Fautrel B, Guillemin F, Durieux P,
Dougados M, Ravaud P: Effect of adherence to European treatment
recommendations on early arthritis outcome: data from the ESPOIR
cohort. Ann Rheum Dis 2012, 71:1803-1808.
14. Le Loet X, Berthelot JM, Cantagrel A, Combe B, De Bandt M, Fautrel B,
Flipo RM, Liote F, Maillefert JF, Meyer O, Saraux A, Wendling D, Guillemin F:
Clinical practice decision tree for the choice of the first disease modifying
antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of
the French Society of Rheumatology. Ann Rheum Dis 2006, 65:45-50.
15. Gaujoux-Viala C, Smolen JS, Landewe R, Dougados M, Kvien TK, Mola EM,
Scholte-Voshaar M, van Riel P, Gossec L: Current evidence for the
management of rheumatoid arthritis with synthetic disease-modifying
antirheumatic drugs: a systematic literature review informing the EULAR
recommendations for the management of rheumatoid arthritis. Ann
Rheum Dis 2010, 69:1004-1009.
16. Kuriya B, Arkema EV, Bykerk VP, Keystone EC: Efficacy of initial
methotrexate monotherapy versus combination therapy with a
biological agent in early rheumatoid arthritis: a meta-analysis of clinical
and radiographic remission. Ann Rheum Dis 2011, 69:1298-1304.
17. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-
Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L,
Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-
Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van
Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al: EULAR
recommendations for the management of rheumatoid arthritis with
synthetic and biological disease-modifying antirheumatic drugs. Ann
Rheum Dis 2011, 69:964-975.
18. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM,
Worthy G, Landewe R, Smolen JS, Emery P, Buch MH: Current evidence for
the management of rheumatoid arthritis with biological disease-
modifying antirheumatic drugs: a systematic literature review informing
the EULAR recommendations for the management of RA. Ann Rheum Dis
2010, 69:976-986.
19. Soubrier M, Puechal X, Sibilia J, Mariette X, Meyer O, Combe B, Flipo RM,
Mulleman D, Berenbaum F, Zarnitsky C, Schaeverbeke T, Fardellone P,
Dougados M: Evaluation of two strategies (initial methotrexate
monotherapy vs its combination with adalimumab) in management of
early active rheumatoid arthritis: data from the GUEPARD trial.
Rheumatology (Oxford) 2009, 48:1429-1434.
20. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L,
Waltbrand E, Zickert A, Theander J, Thorner A, Hellstrom H, Teleman A,
Dackhammar C, Akre F, Forslind K, Ljung L, Oding R, Chatzidionysiou A,
Wornert M, Bratt J: Addition of infliximab compared with addition of
sulfasalazine and hydroxychloroquine to methotrexate in patients with
early rheumatoid arthritis (Swefot trial): 1-year results of a randomised
trial. Lancet 2009, 374:459-466.
21. Moreland LW, O’Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW,
Bridges LJ, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS, TEAR
Investigators: A randomized comparative effectiveness study of oral
triple therapy versus etanercept plus methotrexate in early, aggressive
rheumatoid arthritis. Arthritis Rheum 2012, 64:2824-2835.
22. Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, White M,
Sizto S, Liang MH: Treatment of very early rheumatoid arthritis with
symptomatic therapy, disease-modifying antirheumatic drugs, or
biologic agents: a cost-effectiveness analysis. Ann Intern Med 2009,
151:612-621.
23. van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C,
Krahn M: Cost-effectiveness of biologic response modifiers compared to
disease-modifying antirheumatic drugs for rheumatoid arthritis: a
systematic review. Arthritis Care Res (Hoboken) 2011, 63:65-78.
24. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS: A pilot risk model
for the prediction of rapid radiographic progression in rheumatoid
arthritis. Rheumatology (Oxford) 2009, 48:1114-1121.
25. Sharp JT, Bluhm GB, Brook A, Brower AC, Corbett M, Decker JL, Genant HK,
Gofton JP, Goodman N, Larsen A, et al: Reproducibility of multiple-
observer scoring of radiologic abnormalities in the hands and wrists of
patients with rheumatoid arthritis. Arthritis Rheum 1985, 28:16-24.
26. Sharp JT, Wolfe F, Mitchell DM, Bloch DA: The progression of erosion and
joint space narrowing scores in rheumatoid arthritis during the first
twenty-five years of disease. Arthritis Rheum 1991, 34:660-668.
27. van den Broek M, Dirven L, Dehpoor A, de Vries-Bouwstra J, Goekoop-
Ruiterman Y, Peeters A, Kerstens P, Huizinga T, Lems W, Allaart C: Eight
year results of disease activity steered treatment in a large recent
rheumatoid arthritis cohort: clinical and radiological outcomes. Arthritis
Rheum 2011, 63(Suppl):S157.
28. Tobon G, Saraux A, Lukas C, Gandjbakhch F, Mariette X, Combe B,
Devauchelle-Pensec V: First year radiological erosive progression is a new
predictor of further erosive progression in early arthritis: results of the
ESPOIR cohort. Arthritis Rheum 2011, 63(Suppl):S874.
29. Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P,
Petersson IF, Bratt J, van Vollenhoven RF: Predictors of response to
methotrexate in early DMARD naive rheumatoid arthritis: results from
the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 2011,
70:469-475.
30. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE,
Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF: A matrix risk model for
the prediction of rapid radiographic progression in patients with
rheumatoid arthritis receiving different dynamic treatment strategies:
post hoc analyses from the BeSt study. Ann Rheum Dis 2010,
69:1333-1337.
31. Rezaei H, Saevarsdottir S, Forslind K, Albertsson K, Wallin H, Bratt J,
Ernestam S, Geborek P, Pettersson IF, van Vollenhoven RF: In early
rheumatoid arthritis, patients with a good initial response to
methotrexate have excellent 2-year clinical outcomes, but radiological
progression is not fully prevented: data from the methotrexate
responders population in the SWEFOT trial. Ann Rheum Dis 2011,
71:186-191.
Fautrel et al. Arthritis Research & Therapy 2012, 14:R249
http://arthritis-research.com/content/14/6/R249
Page 8 of 9
32. Lillegraven S, Prince F, Shadick N, Haavardsholm E, Frits M, Iannaccone C,
Kvien T, Weinblatt M, Solomon D: The performance of matrix-based risk
models for rapid radiographic progression in an observational cohort of
established rheumatoid arthritis patients. Arthritis Rheum 2011, 63:S1010.
33. Combe B, Benessiano J, Berenbaum F, Cantagrel A, Daures JP, Dougados M,
Fardellone P, Fautrel B, Flipo RM, Goupille P, Guillemin F, Le Loet X,
Logeart I, Mariette X, Meyer O, Ravaud P, Rincheval N, Saraux A,
Schaeverbeke T, Sibilia J: The ESPOIR cohort: a ten-year follow-up of early
arthritis in France: methodology and baseline characteristics of the 813
included patients. Joint Bone Spine 2007, 74:440-445.
34. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB,
van Riel PL: Modified disease activity scores that include twenty-eight-
joint counts. Development and validation in a prospective longitudinal
study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
35. Fries JF, Spitz P, Kraines RG, Holman HR: Measurement of patient outcome
in arthritis. Arthritis Rheum 1980, 23:137-145.
36. van der Heijde DM: Joint erosions and patients with early rheumatoid
arthritis. Br J Rheumatol 1995, 34:74-78.
37. van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB:
Radiographic progression on radiographs of hands and feet during the
first 3 years of rheumatoid arthritis measured according to Sharp’s
method (van der Heijde modification). J Rheumatol 1995, 22:1792-1796.
38. Durnez A, Vanderschueren G, Lateur L, Westhovens R, Verschueren P:
Effectiveness of initial treatment allocation based on expert opinion for
prevention of rapid radiographic progression in daily practice of an
early RA cohort. Ann Rheum Dis 2011, 70:634-637.
39. Pincus T: Rheumatoid arthritis: a medical emergency? Scand J Rheumatol
Suppl 1994, 100:21-30.
40. Lukas C, Guillemin F, Landewe R, van der Heijde D, Logeart I, Fautrel B,
Daures JP, Combe B: Factors determining a DMARD initiation in early
inflammatory arthritis patients. The ESPOIR cohort study. Clin Exp
Rheumatol 2009, 27:84-91.
41. Saevarsdottir S, Forslind K, Albertsson K, Rezaei H, Engström A, Geborek P,
Petersson I, Emestam S, Bratt J, van Vollenhoven RF: Development of a
matrix risk model to predict rapid radiographic progression in early
rheumatoid arthritis. Results from a randomized trial population. Arthritis
Rheum 2011, 63:S983.
42. Soubrier M, Lukas C, Sibilia J, Fautrel B, Roux F, Gossec L, Patternotte S,
Dougados M: Disease activity score-driven therapy versus routine care in
patients with recent-onset active rheumatoid arthritis: data from the
GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011, 70:611-615.
43. Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J:
Meta-analysis of tight control strategies in rheumatoid arthritis:
protocolized treatment has additional value with respect to the clinical
outcome. Rheumatology (Oxford) 2010, 49:2154-2164.
44. Bombardier C, Li X, Gregersen P, van der Heijde D, Chen M: A risk model
for the prediction of radiographic progression: results from SONORA
study. Arthritis Rheum 2009, 61:S276.
45. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM: How to diagnose
rheumatoid arthritis early: a prediction model for persistent (erosive)
arthritis. Arthritis rheum 2002, 46:357-365.
46. Klareskog L, Catrina AI, Paget S: Rheumatoid arthritis. Lancet 2009,
373:659-672.
47. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J,
Ronnelid J, Harris HE, Ulfgren AK, Rantapaa-Dahlqvist S, Eklund A,
Padyukov L, Alfredsson L: A new model for an etiology of rheumatoid
arthritis: smoking may trigger HLA-DR (shared epitope)-restricted
immune reactions to autoantigens modified by citrullination. Arthritis
Rheum 2006, 54:38-46.
48. Saevarsdottir S, Wedren S, Seddighzadeh M, Bengtsson C, Wesley A,
Lindblad S, Askling J, Alfredsson L, Klareskog L: Patients with early
rheumatoid arthritis who smoke are less likely to respond to treatment
with methotrexate and tumor necrosis factor inhibitors: observations
from the Epidemiological Investigation of Rheumatoid Arthritis and the
Swedish Rheumatology Register cohorts. Arthritis Rheum 2011, 63:26-36.
49. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J,
Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT,
Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martin-Mola EM,
Mielants H, Muller-Ladner U, Murphy G, Ostergaard M, Pereira IA, Ramos-
Remus C, Valentini G, Zochling J, Dougados M: Multinational evidence-
based recommendations for the use of methotrexate in rheumatic
disorders with a focus on rheumatoid arthritis: integrating systematic
literature research and expert opinion of a broad international panel of
rheumatologists in the 3E Initiative. Ann Rheum Dis 2009, 68:1086-1093.
50. Jacobs JW, van Everdingen AA, Verstappen SM, Bijlsma JW: Followup
radiographic data on patients with rheumatoid arthritis who
participated in a two-year trial of prednisone therapy or placebo. Arthritis
Rheum 2006, 54:1422-1428.
51. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van
Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den
Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S:
Randomised comparison of combined step-down prednisolone,
methotrexate and sulphasalazine with sulphasalazine alone in early
rheumatoid arthritis. Lancet 1997, 350:309-318.
52. Bakker MF, Jacobs JW, Welsing PMJ, Verstappen SM, Tekstra J, Ton E,
Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangier ZN, van der
Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW: Double-blind randomized
CAMERA-II trial: better control of disease and erosive joint damage with
inclusion of low-dose prednisone into a MTX-based tight control
strategy for early rheumatoid arthritis. Arthritis Rheum 2011, 63:S663.
53. Emery P: Evidence supporting the benefit of early intervention in
rheumatoid arthritis. J Rheumatol (Suppl) 2002, 66:3-8.
54. Goldbach-Mansky R, Lee JM, Hoxworth JM, Smith D, Duray P,
Schumacher RH Jr, Yarboro CH, Klippel J, Kleiner D, El-Gabalawy HS: Active
synovial matrix metalloproteinase-2 is associated with radiographic
erosions in patients with early synovitis. Arthritis Res 2000, 2:145-153.
doi:10.1186/ar4092
Cite this article as: Fautrel et al.: Matrix to predict rapid radiographic
progression of early rheumatoid arthritis patients from the community
treated with methotrexate or leflunomide: results from the ESPOIR
cohort. Arthritis Research & Therapy 2012 14:R249.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Fautrel et al. Arthritis Research & Therapy 2012, 14:R249
http://arthritis-research.com/content/14/6/R249
Page 9 of 9
